In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)
In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham's Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions. The class ...
Joseph T. Lukens, Peter Kohn at New York office
Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.)
In the Namenda case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis' memantine hydrochloride, sold under the brand name Namenda and Namenda XR. The complaint alleges that Actavis engaged in ...
Joseph T. Lukens, Peter Kohn at New York office
In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.)
In the Loestrin case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Warner Chilcott's oral contraceptive drug, Loestrin 24 Fe. The class alleges that Warner Chilcott and would-be generic competitors ...
Neill W. Clark, Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)
In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories' triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6). Faruqi & Faruqi filed the first direct ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., No. 13-cv-2445 (E.D. Pa.)
In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Reckitt Benckiser's opioid addiction drug, Suboxone. The proposed class alleges that Reckitt took several actions to suppress competition ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Lipitor Antitrust Litigation, No. 12-2389 (PGS/DEA) (D.N.J.)
In this case, nicknamed Lipitor, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer's branded blockbuster cholesterol drug Lipitor (atorvastatin calcium), and direct purchasers of generic Lipitor ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Effexor XR Antitrust Litigation, No. 11-cv-5479 (D.N.J.)
In the Effexor XR case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Wyeth's (now Pfizer's) branded antidepressant drug Effexor XR (extended-release venlafaxine hydrochloride capsules). The class ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re AndroGel Antitrust Litigation (II), 09-md-2084 (N.D. Ga.)
In the Androgel litigation, Faruqi & Faruqi, LLP represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott's branded testosterone drug, AndroGel. The case alleges that Abbott's predecessor filed baseless patent litigation ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office